

SEQUENOM INC  
Form SC TO-T/A  
August 26, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**SCHEDULE TO**  
**(Amendment No. 4)**  
**TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Sequenom, Inc.**  
**(Name of Subject Company (Issuer))**

**Savoy Acquisition Corp.**  
**Laboratory Corporation of America Holdings**  
**(Name of Filing Persons (Offeror))**

**Common Stock, par value \$0.001 per share,**  
**and associated preferred stock purchase rights**  
**(Title of Class of Securities)**

**817337405**

(CUSIP Number of Class of Securities)

**F. Samuel Eberts III**

**Senior Vice President, Chief Legal Officer and Secretary**

**Laboratory Corporation of America Holdings**

**358 South Main Street**

**Burlington, North Carolina 27215**

**(336) 229-1127**

**(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)**

*with copies to:*

**Michael J. Silver**

**William I. Intner**

**John H. Booher**

**G. Allen Hicks**

**Hogan Lovells US LLP**

**875 Third Avenue**

**New York, New York 10022**

**(212) 918-3000**

#### **CALCULATION OF FILING FEE**

**Transaction Valuation\***

\$369,642,070.50

**Amount of Filing Fee\*\***

\$37,222.96

\* Estimated solely for purposes of calculating the filing fee. The transaction value was calculated by adding (i) 119,243,357 shares of common stock (including shares issued as restricted stock awards) of Sequenom, Inc. ( Sequenom ), par value \$0.0001 per share, multiplied by the offer price of \$2.40 per share, (ii) 4,424,325 shares of common stock issuable pursuant to outstanding options with an exercise price less than the offer price of \$2.40 per share, multiplied by \$0.82 per share, which is the offer price of \$2.40 per share minus the weighted average

Edgar Filing: SEQUENOM INC - Form SC TO-T/A

exercise price for such options of \$1.58 per share, (iii) 5,005,493 shares of common stock subject to issuance pursuant to restricted stock units, multiplied by the offer price of \$2.40 per share, (iv) 168,663 shares of common stock estimated to be subject to outstanding purchase rights under an employee stock purchase plan, multiplied by the offer price of \$2.40 per share, and (v) 28,088,372 shares of common stock issuable upon the exercise of convertible notes, multiplied by the offer price of \$2.40 per share. The calculation of the filing fee is based on information provided by Sequenom as of July 25, 2016.

\*\* The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended (the Exchange Act ), and Fee Rate Advisory #1 for fiscal year 2016, issued August 27, 2015, by multiplying the transaction value by 0.0001007.

x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid.

Identify the previous filing by registration statement number or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$37,222.96

Filing Party: Savoy Acquisition Corp.  
and Laboratory Corporation of America  
Holdings

Form of Registration No.: Schedule TO

Date Filed: August 9, 2016

.. Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

- x third-party tender offer subject to Rule 14d-1.
- .. issuer tender offer subject to Rule 13e-4.
- .. going-private transaction subject to Rule 13e-3.
- .. amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ..

If applicable, check the appropriate boxes below to designate the appropriate rule provisions relied upon:

- .. Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
- .. Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment No. 4 (this Amendment No. 4) amends and supplements the Tender Offer Statement on Schedule TO filed on August 9, 2016 (as amended by Amendment No. 1 filed on August 16, 2016, Amendment No. 2 filed on August 19, 2016 and Amendment No. 3 filed on August 23, 2016, the Schedule TO) in connection with the offer (the Offer) by Savoy Acquisition Corp., a Delaware corporation (Purchaser) and a direct wholly owned subsidiary of Laboratory Corporation of America Holdings, a Delaware corporation (LabCorp), to purchase all outstanding shares of common stock, par value \$0.001 per share, of Sequenom, Inc., a Delaware corporation (Sequenom), including the associated preferred stock purchase rights (the Rights) issued under the Rights Agreement, dated March 3, 2009, as amended, between Sequenom and American Stock Transfer & Trust Company, LLC, as rights agent (such Rights, together with the shares of Sequenom's common stock, the Shares), at a price of \$2.40 per Share net to the seller in cash, without interest thereon and subject to any tax withholding, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated August 9, 2016 (the Offer to Purchase), a copy of which is filed with and attached to the Schedule TO as Exhibit (a)(1)(A) thereto, and the related Letter of Transmittal and instructions thereto, a copy of which is filed with and attached to the Schedule TO as Exhibit (a)(1)(B) thereto, as they may be amended or supplemented from time to time. This Amendment No. 4 is being filed on behalf of Purchaser and LabCorp.

The information set forth in the Schedule TO remains unchanged, except that such information is hereby amended and supplemented to the extent specifically provided herein. All capitalized terms used in this Amendment No. 4 without definition have the meanings ascribed to them in the Schedule TO.

#### **Item 11. Additional Information.**

Item 11 of the Schedule TO is hereby amended and supplemented by adding the following paragraphs to the end of Section 15 Certain Legal Matters Legal Proceedings of the Offer to Purchase:

On August 24, 2016, two additional putative class action lawsuits were filed by single plaintiffs in the United States District Court for the Southern District of California (styled *Kenneth Nunes v. Sequenom, Inc., et al.*, Case No. 3:16-cv-02128-AJB-MDD and *Joseph Cusumano v. Sequenom, Inc., et al.*, Case No. 3:16-cv-02134-LAB-JMA) against Sequenom and individual members of Sequenom's Board of Directors. The *Nunes* action also names LabCorp and Purchaser as defendants. Both lawsuits allege that (i) the respective defendants violated Sections 14(e) and 14(d)(4) of the Exchange Act and Rule 14D-9 thereunder by causing a materially incomplete and misleading Recommendation Statement to be filed with the SEC with regard to, among other things, (a) the sales process leading to the proposed sale of Sequenom to LabCorp, including the negotiation of employment opportunities for Sequenom officers, directors or employees following the consummation of the transaction and (b) the valuation of Sequenom and (ii) individual members of Sequenom's Board of Directors and, with respect to the *Nunes* action, LabCorp and Purchaser, violated Section 20(a) of the Exchange Act because they had the power to influence and control and did influence and control, directly or indirectly, the content and dissemination of the Recommendation Statement. The *Cusumano* action also alleges that the individual members of Sequenom's Board of Directors violated the fiduciary duties of care, loyalty, good faith and independence owed to Sequenom's stockholders by putting their personal interests ahead of the interests of Sequenom and its stockholders.

The plaintiffs in both the *Nunes* and *Cusumano* lawsuits seek, among other things, (i) injunctions against the proposed sale of Sequenom to LabCorp, (ii) rescission of the sale and/or an award of rescissory damages in the case that the sale has already been consummated and (iii) an award of reasonable attorneys' and experts' fees. The plaintiff in the *Cusumano* action also seeks an accounting of all damages caused by defendants and of all profits and any special benefits obtained as a result of defendants' breaches of fiduciary duties in an unspecified amount.

On August 25, 2016, the plaintiffs in both the *Malkoff* and *Gupta* lawsuits withdrew their motions for preliminary injunctions.

**SIGNATURES**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**LABORATORY CORPORATION OF AMERICA HOLDINGS**

By: /s/ F. Samuel Eberts III  
Name: F. Samuel Eberts III

Title: Senior Vice President, Chief Legal Officer  
and Secretary

Dated: August 26, 2016

**SAVOY ACQUISITION CORP.**

By: /s/ F. Samuel Eberts III  
Name: F. Samuel Eberts III

Title: President and Secretary

Dated: August 26, 2016